DividendMapper
Moelis & Company logo

MC

Moelis & Company

  • Financial
  • US companies in Financial - Capital Markets (14)
  • NYSE · USD
  • Mkt cap $4.1bn

$55.25

as of 26 Oct 2026, 29% below its 52-week high

Screens as less well placed to keep growing its dividend, though its cut-risk signals are low.

These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.

Trailing yield
4.71%Last 12 months of regular payments at today's price
Forward yield
4.83%Each payment expected in the next 12 months, not the latest one doubled
Cash cover
2.0×Free cash flow over dividends paid
Earnings cover
1.1×Insurers and banks set dividends from capital generation, so their accounting earnings can sit well below the payout.
5y dividend growth
+3.8% a yearMeasured from a cut in FY2020
Next ex-dividend date
Estimated10 Nov 2026Quarterly dividend of about $0.67

Compared with US companies in Financial - Capital Markets (14)

  • Trailing yield is higher than 11 of the 12 other US companies in Financial - Capital Markets with a yield figure.
  • 5y dividend growth (as paid) is lower than 8 of the 12 other US companies in Financial - Capital Markets with a 5y growth figure.

Quality

49

Low

Capacity to keep growing the dividend

Risk

20

Low

Signals of dividend-cut pressure

Trim

38

Low

How extended the valuation looks

Why Quality is 49

MC against US companies in Financial - Capital Markets (14)

Valuation against its own history

As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of MC’s past readings.

  • P/E21.7×P56, neutral for this measure
  • Yield3.97%P12, poor for this measure
  • FCF payout49.9%P17, good for this measure
  • DGR 5y-14.6%P1, poor for this measure
  • ROIC19.6%P33, neutral for this measure
Open valuation history

Forecast your income with the MC dividend calculator

Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.